CA2691474A1 - Cyanoisoquinoleine - Google Patents

Cyanoisoquinoleine Download PDF

Info

Publication number
CA2691474A1
CA2691474A1 CA002691474A CA2691474A CA2691474A1 CA 2691474 A1 CA2691474 A1 CA 2691474A1 CA 002691474 A CA002691474 A CA 002691474A CA 2691474 A CA2691474 A CA 2691474A CA 2691474 A1 CA2691474 A1 CA 2691474A1
Authority
CA
Canada
Prior art keywords
dimethoxy
carbonitrile
isoquinoline
piperazin
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002691474A
Other languages
English (en)
Other versions
CA2691474C (fr
Inventor
Jan Kehler
Jacob Nielsen
Morten Langgaard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2691474A1 publication Critical patent/CA2691474A1/fr
Application granted granted Critical
Publication of CA2691474C publication Critical patent/CA2691474C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2691474A 2007-09-19 2008-09-18 Cyanoisoquinoleine Expired - Fee Related CA2691474C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200701348 2007-09-19
DKPA200701348 2007-09-19
PCT/DK2008/050225 WO2009036766A1 (fr) 2007-09-19 2008-09-18 Cyanoisoquinoléine

Publications (2)

Publication Number Publication Date
CA2691474A1 true CA2691474A1 (fr) 2009-03-26
CA2691474C CA2691474C (fr) 2013-09-10

Family

ID=40011353

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2691474A Expired - Fee Related CA2691474C (fr) 2007-09-19 2008-09-18 Cyanoisoquinoleine

Country Status (8)

Country Link
EP (1) EP2203438A1 (fr)
JP (1) JP2010539195A (fr)
CN (1) CN101743239A (fr)
AR (1) AR068466A1 (fr)
CA (1) CA2691474C (fr)
CL (1) CL2008002809A1 (fr)
TW (1) TW200918519A (fr)
WO (1) WO2009036766A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858620B2 (en) * 2007-09-19 2010-12-28 H. Lundbeck A/S Cyanoisoquinoline
TW201215607A (en) * 2010-07-02 2012-04-16 Lundbeck & Co As H Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
BR112013021180A2 (pt) * 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
CA2852820A1 (fr) 2011-11-09 2013-05-16 AbbVie Deutschland GmbH & Co. KG Carboxamides heterocycliques utiles comme inhibiteurs de la phosphodiesterase de type 10a
UY34980A (es) 2012-08-17 2014-03-31 Abbvie Inc Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
KR20150056844A (ko) 2012-09-17 2015-05-27 아비에 도이치란트 게엠베하 운트 콤파니 카게 포스포디에스테라제 타입 10a의 신규 억제제 화합물
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
MX2015012008A (es) 2013-03-14 2016-04-15 Abbvie Deutschland Compuestos inhibidores novedosos de fosfodiesterasa tipo 10a.
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US20210379061A1 (en) 2018-09-28 2021-12-09 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128695A1 (en) * 2002-10-30 2006-06-15 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
UA86591C2 (ru) * 2003-06-30 2009-05-12 Алтана Фарма Аг Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
WO2005012485A2 (fr) * 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
CA2568929A1 (fr) * 2004-06-07 2005-12-22 Pfizer Products Inc. Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
AU2007223801A1 (en) * 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors

Also Published As

Publication number Publication date
EP2203438A1 (fr) 2010-07-07
WO2009036766A1 (fr) 2009-03-26
CA2691474C (fr) 2013-09-10
AR068466A1 (es) 2009-11-18
JP2010539195A (ja) 2010-12-16
CL2008002809A1 (es) 2009-11-27
CN101743239A (zh) 2010-06-16
TW200918519A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
CA2691474C (fr) Cyanoisoquinoleine
EP2057153B1 (fr) Derivés (3-aryl-piperazin-1-yl) de la 6,7-dialcoxyquinazoline, 6,7-dialcoxyphtalazine et 6,7-dialcoxyisoquinoline
US8841297B2 (en) Phenylimidazole derivative as PDE10A enzyme inhibitor
AU2010262190B2 (en) Novel phenylimidazole derivative as PDE10A enzyme inhibitor
AU2010333437B2 (en) 2-arylimidazole derivatives as PDE10A enzyme inhibitors
KR101998441B1 (ko) 항정신병제로서의 피페라진-치환된 벤조티오펜 유도체
EP2513106B1 (fr) Dérivés hétéroaromatiques d'aryltriazole en tant qu'inhibiteurs de l'enzyme pde10a
KR101324329B1 (ko) 삼치환된 피리미딘 화합물 및 ｐｄｅ10 억제제로서의 그의 용도
KR101363091B1 (ko) 헤테로아릴 치환된 피리다지논 유도체
KR20150011838A (ko) 탄키라아제 억제제로서의 피롤로피라존
CN102256948A (zh) 用作nk3拮抗剂的异喹啉酮衍生物
US7858620B2 (en) Cyanoisoquinoline
WO2012000519A1 (fr) Dérivés d'arylamide et d'hétéroarylamide utilisés comme inhibiteurs de l'enzyme pde10a
EP3810275B1 (fr) Composés de 2,3-dihydrofuro[2,3-b]pyridine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150918